Concentration Of Credit Risk And Significant Customers

6 Months Ended

Jun. 30, 2011

Concentration Of Credit Risk And Significant Customers [Abstract]

Concentration Of Credit Risk And Significant Customers

Note 3 — Concentration of Credit Risk and Significant Customers

We operate in an industry that is highly regulated, competitive and rapidly changing and involves numerous risks and uncertainties. Significant technological and/or regulatory changes, the emergence of competitive products and other factors could negatively impact our consolidated financial position or results of operations.

We have been dependent on our collaborative agreements with a limited number of third parties for a substantial portion of our revenue, and our discovery and development activities may be delayed or reduced if we do not maintain successful collaborative arrangements. We had revenue from customers, as a percentage of total revenue, as follows:

	Three Months Ended June 30,						Six Months Ended June 30,
	2010			2011			2010			2011
Debiopharm		0	%		65	%		0	%		40	%
Astra Zeneca		0	%		0	%		0	%		17	%
Par Pharmaceuticals		57	%		0	%		53	%		0	%
Undisclosed Partner #1		0	%		0	%		10	%		15	%
Undisclosed Partner #2		0	%		0	%		8	%		0	%
Pfizer		13	%		0	%		6	%		0	%
Other		30	%		35	%		23	%		28	%
Total		100	%		100	%		100	%		100	%